Cipla has received final USFDA approval to market generic Bupropion Hydrochloride extended release tablets used for treatment of major depressive disorder through its subsidiary InvaGen Pharmaceuticals Inc. The company’s tablets are generic versions of Valeant’s Wellbutrin XL tablets in the same strengths. The tablets are indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD). Wellbutrin XL tablets and generic equivalents had US sales of approximately $792 million for the 12 month period ending June 2016.
Company Profile : Cipla Ltd
Leave a Reply